Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Rohit Bakshi, M.D.

Co-Author

This page shows the publications co-authored by Rohit Bakshi and Shahamat Tauhid.
Connection Strength

7.583
  1. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. J Neurol. 2015 Nov; 262(11):2425-32.
    View in: PubMed
    Score: 0.643
  2. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis. J Neurol Sci. 2014 Nov 15; 346(1-2):250-4.
    View in: PubMed
    Score: 0.605
  3. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol. 2021 Sep 04.
    View in: PubMed
    Score: 0.246
  4. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol. 2020 Oct; 267(10):2790-2796.
    View in: PubMed
    Score: 0.225
  5. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Mult Scler. 2020 02; 26(2):177-187.
    View in: PubMed
    Score: 0.217
  6. Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study. Neurol Neuroimmunol Neuroinflamm. 2019 09; 6(5):e587.
    View in: PubMed
    Score: 0.211
  7. Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study. Neurol Neuroimmunol Neuroinflamm. 2019 Sep; 6(5).
    View in: PubMed
    Score: 0.211
  8. The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. J Neurol Sci. 2019 Aug 15; 403:38-43.
    View in: PubMed
    Score: 0.208
  9. MRI phenotypes in MS: Longitudinal changes and miRNA signatures. Neurol Neuroimmunol Neuroinflamm. 2019 03; 6(2):e530.
    View in: PubMed
    Score: 0.206
  10. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines. PLoS One. 2018; 13(11):e0206939.
    View in: PubMed
    Score: 0.202
  11. 18F-PBR06 Versus 11C-PBR28 PET for Assessing White Matter Translocator Protein Binding in Multiple Sclerosis. Clin Nucl Med. 2018 Sep; 43(9):e289-e295.
    View in: PubMed
    Score: 0.199
  12. Whole-brain atrophy assessed by proportional- versus registration-based pipelines from 3T MRI in multiple sclerosis. Brain Behav. 2018 08; 8(8):e01068.
    View in: PubMed
    Score: 0.198
  13. Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. eNeurologicalSci. 2018 Sep; 12:42-46.
    View in: PubMed
    Score: 0.197
  14. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. J Neurol Sci. 2017 Dec 15; 383:221-229.
    View in: PubMed
    Score: 0.188
  15. Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability. BMC Neurol. 2017 Sep 05; 17(1):172.
    View in: PubMed
    Score: 0.186
  16. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. J Neuroimaging. 2017 09; 27(5):481-485.
    View in: PubMed
    Score: 0.180
  17. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. JAMA Neurol. 2017 03 01; 74(3):275-285.
    View in: PubMed
    Score: 0.180
  18. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. Int J Neurosci. 2017 Nov; 127(11):971-980.
    View in: PubMed
    Score: 0.179
  19. The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis. Neurol Ther. 2016 Dec; 5(2):215-229.
    View in: PubMed
    Score: 0.175
  20. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis. BMC Med Imaging. 2016 10 05; 16(1):56.
    View in: PubMed
    Score: 0.175
  21. The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging. 2017 01; 27(1):33-36.
    View in: PubMed
    Score: 0.172
  22. The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis. Front Neurol. 2016; 7:99.
    View in: PubMed
    Score: 0.171
  23. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. Int J Neurosci. 2017 May; 127(5):396-403.
    View in: PubMed
    Score: 0.170
  24. Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016 Apr; 3(2):e200.
    View in: PubMed
    Score: 0.167
  25. An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis. J Neurol. 2016 Mar; 263(3):531-8.
    View in: PubMed
    Score: 0.166
  26. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. J Neuroimaging. 2016 Mar-Apr; 26(2):184-7.
    View in: PubMed
    Score: 0.163
  27. T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis. BMC Neurol. 2015 Jul 31; 15:124.
    View in: PubMed
    Score: 0.161
  28. Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis. J Neuroimaging. 2016 Jan-Feb; 26(1):62-7.
    View in: PubMed
    Score: 0.160
  29. MRI detection of hypointense brain lesions in patients with multiple sclerosis: T1 spin-echo vs. gradient-echo. Eur J Radiol. 2015 Aug; 84(8):1564-1568.
    View in: PubMed
    Score: 0.159
  30. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport. 2014 Oct 01; 25(14):1156-61.
    View in: PubMed
    Score: 0.152
  31. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.126
  32. Approaches to normalization of spinal cord volume: application to multiple sclerosis. J Neuroimaging. 2012 Jul; 22(3):e12-9.
    View in: PubMed
    Score: 0.122
  33. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2011 Apr; 21(2):e50-6.
    View in: PubMed
    Score: 0.119
  34. The relationships among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis. J Neuroimaging. 2012 Apr; 22(2):122-8.
    View in: PubMed
    Score: 0.119
  35. Gut Microbiome in Progressive Multiple Sclerosis. Ann Neurol. 2021 06; 89(6):1195-1211.
    View in: PubMed
    Score: 0.060
  36. Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases. J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9:23247096211033047.
    View in: PubMed
    Score: 0.059
  37. 7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis. Brain. 2020 10 01; 143(10):2973-2987.
    View in: PubMed
    Score: 0.058
  38. Regional microglial activation in the substantia nigra is linked with fatigue in MS. Neurol Neuroimmunol Neuroinflamm. 2020 09 03; 7(5).
    View in: PubMed
    Score: 0.057
  39. Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. Brain. 2019 03 01; 142(3):633-646.
    View in: PubMed
    Score: 0.052
  40. A dual modeling approach to automatic segmentation of cerebral T2 hyperintensities and T1 black holes in multiple sclerosis. Neuroimage Clin. 2018; 20:1211-1221.
    View in: PubMed
    Score: 0.050
  41. Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. Neuroimage. 2019 01 01; 184:901-915.
    View in: PubMed
    Score: 0.050
  42. Dual-Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI. J Neuroimaging. 2018 01; 28(1):36-47.
    View in: PubMed
    Score: 0.047
  43. Gradient nonlinearity effects on upper cervical spinal cord area measurement from 3D T1 -weighted brain MRI acquisitions. Magn Reson Med. 2018 03; 79(3):1595-1601.
    View in: PubMed
    Score: 0.046
  44. Adrenocorticotropic hormone versus methylprednisolone added to interferon ß in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial. Ther Adv Neurol Disord. 2017 Jan; 10(1):3-17.
    View in: PubMed
    Score: 0.044
  45. Quantification of global cerebral atrophy in multiple sclerosis from 3T MRI using SPM: the role of misclassification errors. J Neuroimaging. 2015 Mar-Apr; 25(2):191-199.
    View in: PubMed
    Score: 0.039
  46. Corpus callosum atrophy correlates with gray matter atrophy in patients with multiple sclerosis. J Neuroimaging. 2015 Jan-Feb; 25(1):62-7.
    View in: PubMed
    Score: 0.037
  47. Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult Scler. 2010 Jan; 16(1):39-44.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.